EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Amylin and the amylin receptors in migraine: Is there another pathway to target?

David Moreno-Ajona iD, Helin Gosalia, Jan Hoffmann iD, Peter J Goadsby iD

Cephalalgia · 2025-05 · 45 (5)

DOI: 10.1177/03331024251340066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cephalalgia, online erschienen am 19.05.2025. Verfasst von David Moreno-Ajona und 3 weiteren Autor:innen. Beteiligte Einrichtung: NIHR King's Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute o…. Hauptthemen laut MEDLINE: Migraine Disorders, Islet Amyloid Polypeptide, Receptors, Islet Amyloid Polypeptide. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here, we review the available evidence implicating amylin in migraine, its relationship with calcitonin gene-related peptide (CGRP) and its potential utility as a therapeutic target. The pathophysiology of migraine is currently better understood and the role of CGRP is key. Treatments targeting this pathway have been successful and migraine is a complex disorder, with so many molecules being implicated. Amylin, as for CGRP, is part of the calcitonin/CGRP peptide family. Some therapies intended to block the CGRP pathway can also target amylin receptors. Similar to CGRP, amylin can trigger migraine attacks in a provocation study. Amylin plasma levels have been highlighted as a potential migraine biomarker in one study in migraine patients. Moreover, some preclinical studies in rodents have also discussed sex differences. Comprehending the distinct and overlapping mechanisms between amylin and CGRP signalling could develop further our understanding of migraine pathophysiology. In summary, this review reveals, through initial studies, that targeting the amylin pathway may have a potential role as a novel treatment option for those who may not respond to other treatments, or as a better alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersIslet Amyloid PolypeptideReceptors, Islet Amyloid PolypeptideHumansAnimalsCalcitonin Gene-Related PeptideSignal Transduction

Stichwörter der Autor:innen

amylinamylin receptorbiomarkerspramlintide

Substanzen

Islet Amyloid PolypeptideReceptors, Islet Amyloid PolypeptideCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • NIHR King's Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College, Lon…
  • Department of Neurology, Queen Elizabeth Hospital, London, UK.
  • Department of Neurology, University of California, Los Angeles, CA, USA.

ORCID-Profile: David Moreno-Ajona, Jan Hoffmann, Peter J Goadsby

Zitieren

APA

Moreno-Ajona, D., Gosalia, H., Hoffmann, J., & Goadsby, P. J. (2025). Amylin and the amylin receptors in migraine: Is there another pathway to target?. Cephalalgia, 45(5). https://doi.org/10.1177/03331024251340066

Vancouver

Moreno-Ajona D, Gosalia H, Hoffmann J, Goadsby PJ. Amylin and the amylin receptors in migraine: Is there another pathway to target?. Cephalalgia. 2025;45(5). doi:10.1177/03331024251340066

BibTeX
@article{MorenoAjona2025,
  author = {Moreno-Ajona, David and Gosalia, Helin and Hoffmann, Jan and Goadsby, Peter J},
  title = {Amylin and the amylin receptors in migraine: Is there another pathway to target?},
  journal = {Cephalalgia},
  year = {2025},
  volume = {45},
  number = {5},
  doi = {10.1177/03331024251340066}
}
Kostenlos starten →